Tyler Flores

Despite revenue dips, Sera Prognostics is making strides in securing Medicaid coverage for its PreTRM test, aiming to revolutionize preterm birth risk assessment and improve maternal health outcomes.

A new partnership and promising clinical data are positioning Vaxart as a key player in the emerging oral vaccine market, with implications for infectious disease prevention and global access.

Facing a historically underserved market, Daré Bioscience is pioneering a multi-pronged approach – leveraging 503B compounding, securing substantial grant funding, and developing innovative therapies – to address critical gaps in women's healthcare.

Canadian pharma firm BioSyent Inc. prepares to report Q3 & YTD 2025 earnings. A deep dive into the company's growth strategy, industry headwinds, and future outlook in the rapidly evolving specialty pharmaceutical market.

Epigenetics firm VolitionRx expands commercial reach with strategic alliances and promising financial results, navigating a competitive market with innovative diagnostic technologies.

Medical device firm GlucoTrack plans pivotal FDA submission for its fully implantable glucose monitor, boasting a three-year lifespan & direct blood glucose measurement. The company is strengthening its financial position to support upcoming trials.

Positive Phase 2 data for Elicio Therapeutics' ELI-002 7P in pancreatic cancer, combined with a bolstered cash position, positions the company for growth in the competitive immunotherapy landscape.

Clinical-stage biotech NuCana plc bolsters its cash runway to 2029 while demonstrating promising data for its ProTide cancer therapies, NUC-7738 and NUC-3373, offering hope for patients with difficult-to-treat cancers.

Spero Therapeutics’ tebipenem HBr shows promising Phase 3 results, offering a potential first-in-class oral treatment for complicated urinary tract infections and a new lifeline against antibiotic resistance.

Positive Phase 3 data and expanding applications for Reviva Pharmaceuticals’ brilaroxazine signal a potential breakthrough for schizophrenia treatment and open doors to new markets like pulmonary fibrosis and psoriasis.

Fennec Pharmaceuticals reports strong Q3 2025 results fueled by PEDMARK®, the first FDA-approved therapy for cisplatin-induced hearing loss. Expansion into Europe and Japan signals a bright future, but supply chain vulnerabilities loom.

QUELIMMUNE maker SeaStar Medical reports improved financials and encouraging clinical trial progress for its novel AKI prevention platform. The company is focusing on addressing a critical gap in care for acute kidney injury.

Profound Medical Corp. secures a key distribution agreement in Saudi Arabia as it continues to commercialize its TULSA PRO system for BPH. The company's financial position remains under scrutiny amid ongoing investment in growth.

Facing clinical trial disappointments with its depression drug, Relmada Therapeutics is shifting focus to a promising bladder cancer treatment, NDV-01, while also advancing a program for compulsive disorders. Investors are watching closely.

Despite a revenue dip, Strata Skin Sciences is strategically positioning itself for growth with expanded CPT codes and a focus on recurring revenue. The company's innovative XTRAC system and new TheraClearX device are key to its long-term prospects.

ORIC Pharmaceuticals is making strides in metastatic castration-resistant prostate cancer with its PRC2 inhibitor, ORIC-944, and brain-penetrant lung cancer therapy, enozertinib, bolstered by a strong financial position.

Positive preclinical data for JADE101 and progress on JADE201 have secured a significant investment for Jade Biosciences, positioning the company to advance its autoimmune disease pipeline.

Positive clinical trial results for telitacicept in Sjögren's disease and continued promise in myasthenia gravis, coupled with a significant capital raise, position Vor Bio for potential growth – despite substantial net losses.

NeOnc Technologies completes enrollment in its Phase 2a trial of NEO100, a novel treatment for aggressive brain cancer utilizing intranasal delivery to bypass the blood-brain barrier. Preliminary data expected in Q2 2026.

Positive trial results for prostate cancer, expansion into NSCLC, and a significant debt financing position Candel Therapeutics for a pivotal year in oncology innovation.